Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide and Temozolomide with Radiation for Malignant Gliomas
NCT00275067Phase 2Unknown
- Sponsor
- Northwestern University
- Start
- May 2005
- Primary completion
- May 2021
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of arsenic trioxide in malignant glioma, sponsored by Northwestern University. Status: unknown.
02
Drugs
arsenic trioxide
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT00275067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00275067.